Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

d party contractors for certain goods and services, and any inability of these third party manufacturers to manufacture products, or any failure of these third party contractors to provide these goods and services, in each case in accordance with its respective contractual obligations, could adversely affect Shire's ability to manage its manufacturing processes or to operate its business;
  • the development, approval and manufacturing of Shire's products is subject to extensive oversight by various regulatory agencies and regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
  • the actions of certain customers could affect Shire 's ability to sell or market products profitably and fluctuations in buying or distribution patterns by such customers could adversely impact Shire's revenues, financial conditions or results of operations;
  • investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire's activities in the highly regulated markets in which it operates may result in the distraction of senior management, significant legal costs and the payment of substantial compensation or fines;
  • adverse outcomes in legal matters and other disputes, including Shire's ability to obtain, maintain, enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire's revenues, financial condition or results of operations;
  • and other risks and uncertainties detailed from time to time in Shire's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K.

    i. Fine J-D, Johnson  LB, Suchindran C, Gedde-DahI T (1999e) The Epidemiology of I
    '/>"/>

    SOURCE Shire plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
    2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
    3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
    4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
    5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
    6. Shire Changes its NASDAQ Ticker Symbol to SHPG
    7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
    8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
    9. Shire Reaches Agreement in Principle With U.S. Government
    10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
    11. ODT Forum Presents Regenerative Technologies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/21/2014)... (PRWEB) November 20, 2014 The ... public policy research organization representing leading California academic ... and PwC US today released a ... life sciences industry growth. The trend shows a ... 2015 California Biomedical Industry Report indicates ...
    (Date:11/21/2014)... 21, 2014 Why did Stephen Hawking ... Einstein so instantly recognizable? Why have they become icons ... and author Hilton Ratcliffe seeks out the answers to ... all to do with science. In " Stephen Hawking ... November 21, 2014), Ratcliffe puts it plainly: , ...
    (Date:11/21/2014)... - Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") ... a brokered private placement offering (the "Brokered Offering") ... Securities Inc. and Clarus Securities Inc. acted as ... syndicate of agents that also included Wolverton Securities ... Concurrently with the Brokered Offering, the Company also ...
    (Date:11/18/2014)... November 17, 2014 RPS Diagnostics ... tests – today announces its third annual partnership ... (CDC) Get Smart About Antibiotics Week from November ... a national campaign designed to highlight the coordinated ... and non-profit and for-profit partners to provide education ...
    Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
    ... Universite de Montreal and Validapro Biosciences Inc. have signed an ... standards of the biotherapeutic manufacturing unit located at the Faculty ... veterinary clinical use. , ... Laval, ...
    ... 19 , - Completed ... Opsona Therapeutics, a biotechnology company focused ... diseases, today,announced that Roche Venture Fund and Enterprise Ireland ... financing announced in February,this year, bringing the total round ...
    ... for Mometasone Furoate/Formoterol Combination for Asthma and ... (NYSE: SGP ) today announced ... for the development and commercialization of fixed-dose ... and chronic obstructive pulmonary disease (COPD). ...
    Cached Biology Technology:Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing 2Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing 3Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 2Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 3Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 4Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 5Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 6Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 7Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 8
    (Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
    (Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
    (Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
    Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
    ... 11, 2011, Shenzhen, China BGI (previously known as the ... announced today that it was among the research organizations comprising ... sequence and analysis of the tuber crop potato, published as ... This study marks an important milestone in ...
    ... present in primitive fish millions of years before their ... Genetic switches control the timing and location of ... DNA is placed into mouse embryos, the segment can ... University of Chicago researchers report in Proceedings of ...
    ... researchers at The Wistar Institute shows how our cells create ... DNA. Many genes are associated with multiple gene promoters, the ... a given gene, for example, can be made with the ... journal Genome Research, available online now, show how genes are ...
    Cached Biology News:BGI contributes whole genome sequencing and bioinformatics expertise to potato genome research 2BGI contributes whole genome sequencing and bioinformatics expertise to potato genome research 3Genetic switch for limbs and digits found in ancient fish 2Genetic switch for limbs and digits found in ancient fish 3Multiple 'siblings' from every gene: Alternate gene reading leads to alternate gene products 2Multiple 'siblings' from every gene: Alternate gene reading leads to alternate gene products 3
    ...
    MultiWash III w/ 12-portStandard Manifold...
    ...
    ... Streptavidin Sepharose High Performance, 5 ... media used in HiTrap Streptavidin columns ... compounds.Ideal for packing into Tricorn 5/50 ... when larger scale purifications are required.Extremely ...
    Biology Products: